FOXO3 and glioblastoma: Conversely, in glioblastomas, FOXO3 activation promotes differentiation of CSCs, suppressing their tumorigenicity [120], and in colorectal cancer, FOXO3 activation inhibits CSCs self-renewal by significantly inducing TRAIL and its receptor DR5 [121].